In this March 16, 2020 file photo, a subject receives an injection in the first-stage safety study clinical trial of a possible Moderna vaccine for COVID-19, the disease caused by the new coronavirus, in the Kaiser Permanente Washington Health Research Institute in Seattle.
Ted S. Warren | AP
A Goldman Sachs analyst believes the United States could approve a coronavirus vaccine before the end of the year as the country tries to stem a massive increase in cases.
Data compiled by Johns Hopkins University showed that cases in the United States grew by a staggering 77,200, breaking a one-day record. Cases are increasing in almost all states as authorities reverse measures of social distancing. California, Florida and Texas are some of the most affected states recently. On Thursday alone, they combined for more than 38,000 cases.
The rapid spread of the virus has led the US government to accelerate the development of a possible vaccine, leading Goldman analyst Salveen Richter to believe that “a vaccine can get US approval. In 2H20 “.
Below are some companies highlighted by Goldman Sachs that could get an approved vaccine candidate later this year.
.
